70-80% Reduction In Covaxin Trial Participation: AIIMS
The results of the first phase trial of Covid vaccine candidate Covaxin, developed by Bharat Biotech, show that the vaccine induced an immune response and did not lead to any serious side-effects, this according to a pre-print study published by Bharat Biotech. This has not been peer-reviewed, which means it hasn't been reviewed by a third party. An AIIMS doctor said that for the third phase of trial of the Bharat Biotech vaccine, there's a 70-80 per cent reduction in those volunteering for the test.
